Pharmacokinetics of pidotimod in elderly volunteers and in renal failure patients

D. Spotti, M. Biffi, G. Coppi, S. Silingardi, F. Mailland

Research output: Contribution to journalArticlepeer-review


The pharmacokinetics of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl)carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) in elderly volunteers and in patients with renal failures were investigated. No differences in absorption, excretion and pharmacokinetic parameters was evident between old volunteers and the young of a previous work. Patients with impaired renal function showed different pharmacokinetic parameters of pidotimod in relation to different grade of kidney function. There were linear relationships between elimination half-lives and plasma levels of creatinine and urea; longer half-lives correspond to higher levels of creatinine and urea. As the half-life of the compound did never exceed 8-9 h, the data do not support any change of pidotimod administration schedule (24-12 h).

Original languageEnglish
Pages (from-to)1470-1472
Number of pages3
JournalArzneimittel-Forschung/Drug Research
Issue number12 A
Publication statusPublished - 1994


  • biological response modifiers
  • CAS 121808-62-6
  • PGT/1A
  • pidotimod, pharmacokinetics

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Pharmacokinetics of pidotimod in elderly volunteers and in renal failure patients'. Together they form a unique fingerprint.

Cite this